Lumos develops, manufactures and commercializes custom, rapid point-of-care diagnostic solutions
Joined January 2018
- Tweets172
- Following78
- Followers281
- Likes11
Lumos has closed its A$5.0 million Loan Facility with major shareholders Tenmile Ventures and Ryder Capital, with the balance repaid in full. Lumos now holds no debt. Read the ASX release: bit.ly/LDX_LoanClosure
$LDX #ASX #biotech #medtech #pointofcare #healthcare
Join CEO Doug Ward, Director of U.S. Sales Tommy Hall, and PHASE Scientific's VP of Commercial Operations Bob Gergen on Thursday, 11 June at 10.30am AEST for a live update on the US commercial expansion of FebriDx®. Register here 👉 bit.ly/4o8WdQK
Lumos Diagnostics (ASX:LDX) was featured in a Stockhead’s article titled “Beyond FDA approval: How ASX medical device plays are cracking US market”. It’s worth a read: bit.ly/4wXWVEf #LDX #LumosDiagnostics #FebriDx #MedTech #Diagnostics #PointOfCareTesting
$LDX | #Lumos has released a U.S. rollout update for FebriDx® following FDA CLIA waiver clearance, with encouraging early implementation and reimbursement indicators as the Company builds momentum ahead of the 2026/27 flu season. Read the announcement:
bit.ly/3PvWiAT
Lumos has achieved the 250-patient enrolment milestone in its BARDA-funded FebriDx® paediatric study, triggering a US$670k milestone payment. The study supports potential expansion of FebriDx® in the US.
Read the ASX announcement: bit.ly/4eNDxDo
Lumos has received a US$0.5m non‑dilutive milestone payment from BARDA following US FDA CLIA waiver for FebriDx®. BARDA, a key U.S. health security agency, now has provided ~US$3.0m in support for the FebriDx CLIA program. bit.ly/4tY5BZo
#BARDA #Diagnostics #PointOfCare
Lumos has released its Q3 FY26 Quarterly Activities Report. A defining quarter, with CLIA waiver for FebriDx®, expanding access to ~80M US patients and supporting commercial rollout.
Read more: bit.ly/3OMgIFw
$LDX #Lumos #Diagnostics #MedTech #PointOfCare #Healthcare
Lumos Diagnostics will provide an update on its US commercial rollout at its upcoming Q3 FY26 investor webinar. Following a week of meaningful progress, the Company is now advancing execution across the US.
📅Tue 21 April 2026
🕚11:00am (AEST)
Register: us02web.zoom.us/webinar/regi…
Lumos is pleased to invite eligible shareholders to participate in our Share Purchase Plan (SPP) and Options Offer which opens today, with one free attaching option for every two SPP shares subscribed for.
Please see Offer docs for details: lumosdiagnostics.com/spp
$LDX | @LumosDX announces new contract manufacturing agreement & first purchase order with Micro-Pak.
Read the ASX release: bit.ly/3Ouev1j
$LDX #Lumos #diagnostics #healthcare #manufacturing
Lumos has announced that it has now received its largest purchase order to-date for FebriDx®, with its U.S. exclusive distribution partner PHASE Scientific placing an order valued at US$1.3 million.
Read the ASX release: bit.ly/4uYZq8x
Investor webinar | Lumos will host a webinar on Tuesday 31 March at 9.00am (AEDT) to discuss the FDA CLIA waiver for FebriDx®, followed by a Q&A session.
Register here: us02web.zoom.us/webinar/regi…
$LDX #Lumos #FDA #rapidtest #FebriDx #pointofcare #diagnostics
Lumos has successfully completed a A$20.0 million institutional placement, with strong support from both existing and new investors, with proceeds to support the commercial rollout of FebriDX across the U.S. point-of-care market. Read the ASX announcement: bit.ly/3PqtYzM
Lumos Diagnostics has today announced that U.S. FDA has granted 510(k) clearance with CLIA waiver for FebriDx®, enabling broader use across frontline healthcare settings and unlocking a U.S. market opportunity of over US$1.0 billion.
Read the ASX release: bit.ly/48d11h0
REPLAY | $LDX 1H FY26 Investor Briefing
CEO Doug Ward and CFO Barrie Lambert discuss Lumos’ half-year performance, recent commercial and regulatory milestones, and the key priorities ahead as Lumos works toward CLIA waiver for FebriDx.
Watch the replay: youtu.be/q2WnHtks4DI
Lumos has announced the completion of the first enrollment milestone in the ongoing BARDA-funded paediatric clinical study, triggering a milestone payment of US$720,000.
Read the ASX announcement: bit.ly/3MKrbjF
